Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton MR Spectroscopic Imaging Study

10.1016/S1470-2045(09)70025-7

10.1016/S1548-5315(11)70267-4

10.1634/theoncologist.2009-0121

10.3174/ajnr.A1987

10.3171/2010.9.JNS101223

Riina, 2009, Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma, J Exp Ther Oncol, 8, 145

10.1016/j.wneu.2011.05.056

Fischer, 2008, High-grade glioma before and after treatment with radiation and Avastin: initial observations, J Neurooncol, 10, 700

10.1212/01.wnl.0000208958.29600.87

Wagle, 2010, Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab, Pharmacogenomics Pers Med, 3, 79

de Groot, 2008, Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas, Cancer J, 14, 279, 10.1097/PPO.0b013e3181867bd6

10.1007/s11060-005-5261-2

10.2214/AJR.07.3934

10.2214/AJR.04.0933

10.1093/neuonc/noq075

10.1102/1470-7330.2006.0018

Wen PY MacDonald DR Reardon DA . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J ClinOncol 28: 1963–72

Duyn, 1993, Multisection proton MR spectroscopic imaging of the brain, Radiology, 188, 277, 10.1148/radiology.188.1.8511313

10.1148/rg.26si065513

10.1023/A:1006387703127

10.1602/neurorx.2.2.197

McKnight, 2002, Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence, J Neurosurg, 97, 794, 10.3171/jns.2002.97.4.0794

10.3174/ajnr.A2397

10.1007/s11912-009-0077-4

Macdonald, 1990, Response criteria for phase II studies of supratentorial malignant glioma, J Clin Oncol, 8, 1277, 10.1200/JCO.1990.8.7.1277

Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 227, 4733, 10.1200/JCO.2008.19.8721

10.1016/S1474-4422(10)70181-2

10.1097/WCO.0b013e328318402a